ICUI · ICU Medical, Inc.

ICU Medical’s Q1 2026 results reflect a strategic inflection point following the May 1, 2025 divestiture of its IV Solutions business — a $172.2M contributor to the prior-year Vital Care segment that dropped to $72.3M in Q1 2026. This explains the 12% YoY GAAP revenue decline, though non-GAAP organic revenue grew 1% after adjusting for the divestiture and FX, signaling resilience in core infusion systems and consumables — which together rose $25.4M YoY. Gross margin expanded 400 bps to 39%, driven by higher-margin product mix and cost discipline, offsetting lower volume. The reversal from a $15.5M GAAP net loss to $30.1M net income reflects both margin improvement and reduced restructuring/integration costs ($16.8M vs. $16.7M YoY) amid ongoing Smiths Medical integration. Adjusted EBITDA held nearly flat at $98.7M despite lower top-line, underscoring operating leverage. CEO Vivek Jain stated results were 'generally in line with expectations,' confirming no material guidance revision was issued in the release — consistent with the absence of forward-looking financial outlook language. The balance sheet remains strong, with $288.3M cash and $1.26B long-term debt, and operating cash flow of $38.9M supports continued investment and debt management. No new capital return actions were disclosed.